-Operation system: windows XP(Best) or windows 7 Ultrasound Box,BW ultrasound scanner,ultrasound box,black and white ultrasound box,ultrasound scanner Guangzhou Sonostar Technologies Co., Limited , https://www.sonoeye.com
-D-Maximum Scanning Depth: max. 250mm
-Multi-frequency: 5 segment frequencies
-Zoom: 10 ratio, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0
-Image gray scale: 256 level gray scale
-Cine Loop::max. 1024 frames
-Scann mode: B, 2B, B/M, M, 4B, 9B, ZOOM(Real-time zoom on B mode)
-Image processing: Pre-processing, after-processing, dynamic range, frame rate, line average, edge;
enhancement, Black/White inversion; Gray scale adjustment, contrast, brightness, γ revision.
-Measurement and calculation(human):
B mode: distance, circumstance, area, volume, angle, ratio, stenosis, profile, histogram;
M mode: heart rate, time, distance, slope and stenosis;
Gynecology measurement: Uterus, cervix, endometrium, L/R ovary;
Obstetric: gestation age, fetal weight, AFI;
Cardiology: LV, LV function, LVPW, RVAWT;
Urology: transition zone volume, bladder volume, RUV, prostate, kidney;
Small parts: optic, thyroid, jaw and face.
-Measurement and calculation(veterinary): Cattle: BPD, CRL, TD;
Horse: GA; Dog: GS; Cat: HD, BD; Sheep: BPD, CRL, TD
-Image store: by computer hardisk or USB disk
-Print: by USB laser/inkjet printers with computer
-DICOM3.0, medical digital imaging and communication
-3D image function(function): can get rebuilt 3D image by any probe
Researchers promote personalized treatment of triple-negative breast cancer
Medical Network May 25 In a recent study published in the Journal of Clinical Investigation, Mayo Clinic researchers found that an FDA-approved drug for the treatment of skeletal dysplasia syndrome may be treatable. Triple negative breast cancer, which is the most malignant and deadly type of breast cancer.
In this study, researchers at the Mayo Clinic found that the drug approved by the FDA for the treatment of some blood cancers, decitabine, significantly inhibited the growth of triple-negative breast cancer. In addition, the drug also inhibits tumors that are resistant to chemotherapy. . This response relies on certain proteins called DNA methylation invertases, but this protein is only expressed in a small number of tumors. This also provides a way to find patients who might benefit from this therapy.
“There is an urgent need to find new ways to treat triple-negative breast cancer because it is the most difficult breast cancer to treat,†said Dr. Liewei Wang, a researcher at the Mayo Clinic. "This study shows that by studying the way existing FDA-approved drugs work and applying them to other cancers, we are able to take advantage of many drugs and expand their use."
The study, part of the Breast Cancer Genome-Guided Therapy (BEAUTY) study, was led by Dr. Matthew Goetz, a medical oncologist at Mayo Clinic, and Dr. Judy Boughey, a Mayo Clinic surgeon. The study used an immortalized cancer cell transplant model derived from breast cancer patients treated with chemotherapy. “The risk of breast cancer recurrence and death is extremely high in patients who do not respond to chemotherapy,†Dr. Boughey said. “So our focus is on finding new treatments for these patients.â€
The researchers found that when DNA methylation-converting enzymes are present in these transplant models, decitabine can inhibit the growth of triple-negative breast cancer at very low doses, thereby reducing toxic side effects and thus allowing longer periods of drug use. Both will help improve the therapeutic effect.
Dr. Goetz said they are planning a prospective clinical trial called BEAUTY2 to study the effects of decitabine, focusing on women with triple-negative breast cancer who are resistant to chemotherapy.